23andMe And Celmatix Collaborate To Improve Infertility Outcomes

Companies Join Forces to Validate and Discover Genetic Biomarkers That May Redefine How Infertility is Diagnosed and Treated

NEW YORK--(BUSINESS WIRE)--Celmatix, the only personalized medicine company focused specifically on fertility and women’s health, and 23andMe, Inc., the leading personal genetics company, announced a collaboration today aimed at improving infertility outcomes. This collaboration will accelerate the launch of Celmatix’s tests, which will aim to provide physicians with a comprehensive genetic lens on infertility. This will also enable the development of early screening tests which will help OBGYNs identify women who are at risk for premature decline of their ovarian function, which has both infertility and broader health implications.

“Fertility and women’s health have always been important to 23andMe and our research mission”

According to the CDC, one out of eight couples in the US struggles to conceive. Today, there are no comprehensive genetic tests available to guide the diagnosis and treatment of infertility in women or men.

“The scale of the genetic data that 23andMe has amassed is unprecedented for the field of reproductive medicine,” said Celmatix founder and CEO, Piraye Yurttas Beim, Ph.D. “Celmatix has worked for six years in partnership with the top fertility centers in the world to vet, validate, and discover novel genetic biomarkers that will dramatically impact the diagnosis and treatment of infertility. This collaboration allows us to further accelerate this work with the amazing dedication of the 23andMe research community. Together, we will be able to help more people who are struggling to conceive, have a baby sooner.”

The collaboration will combine Celmatix’s discovery and annotation of more than 5,200 genetic biomarkers related to fertility potential in humans and 23andMe’s robust genetic database and research community.

“Fertility and women’s health have always been important to 23andMe and our research mission,” said Emily Drabant Conley, Ph.D., vice president of business development at 23andMe. “We chose Celmatix as our partner for fertility research because they are the leader in the field of personalized reproductive medicine. Through their big data platform and comprehensive clinic network they have amassed a deep clinical database on infertility treatments – combining that platform with 23andMe’s massive genetic database will create a uniquely powerful engine to fuel discoveries on the genetics of infertility. We believe Celmatix’s vision to provide women with genetic information that can inform proactive fertility management will ultimately have a meaningful impact on infertility outcomes.”

About Celmatix

Celmatix is a personalized medicine company that uses big data and predictive analytics to help individuals who are struggling to have a baby make informed decisions. Founded in 2009 and based in New York City, Celmatix is disrupting the way women approach their lifelong fertility journey by empowering them through science and technology. The company’s digital platform, Polaris, is in use at top fertility clinics across the country, helping them better leverage their data to optimize the patient experience and reach outcomes more efficiently. Celmatix also has an active research and development program dedicated to decoding the genetic basis of fertility potential. For more information, visit www.celmatix.com.

About 23andMe

23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has over one million customers worldwide with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.